Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Information on natalizumab (marketed as Tysabri)
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
Topographical and Biological Evidence Revealed FTY720-Mediated Anergy-Polarization of Mouse Bone Marrow-Derived Dendritic Cells In Vitro.
Motor vehicle operation in the setting of multiple sclerosis with myelopathy: assessment, adaptive equipment, counseling, and cessation of driving.
Spasticity: pathophysiology, evaluation and management.
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Gammaherpesvirus Infection of Human Neuronal Cells.
Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat.
Harnessing monocyte-derived macrophages to control central nervous system pathologies: No longer 'if' but 'how'
What to expect after natalizumab cessation in a real-life setting.
The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients.
Post-Partum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother.
Mesenchymal Stem Cell treatment for autoimmune diseases: a critical review.
ATP increases the migration of microglia across the brain endothelial cell monolayer.
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation.
Laquinimod CHMP/EMA opinion
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
The roles of cathelicidin LL-37 in immune defences and novel clinical applications.
Sexual Behavior, Body Image, and Partnership in Chronic Illness: A Comparison of Huntington's Disease and Multiple Sclerosis.
Large-scale neuronal network dysfunction in multiple sclerosis?: Evidence from resting-state fMRI.
Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
Pages
« first
‹ previous
…
202
203
204
205
206
207
208
209
210
…
next ›
last »